Antony, France (ots/PRNewswire) -

Million EUR 2008 08/07 2009 09/08
MEUR %Sales Var.% MEUR %Sales Var.%
Southern Europe (1) 36.4 73 14 42.4 74 16
Other EU countries (2) 11.3 23 17 13.1 23 16
Other markets 2.0 4 45 1.5 3 (25)
SLIT 40.4 81 17 48.5 85 20
SCIT 7.5 15 6 6.8 12 (10)
Other products 1.8 4 32 1.7 3 (5)
Total Q4 sales 49.7 100 15 57.0 100 15
Million EUR 2008 08/07 2009 09/08
MEUR %Sales Var.% MEUR %Sales Var.%
Southern Europe (1) 124.9 73 14 138.6 72 11
Other EU countries (2) 38.5 23 18 47.6 25 24
Other markets 7.5 4 38 6.7 3 (11)
SLIT 137.9 81 18 160.0 83 16
SCIT 26.3 15 6 25.9 13 (2)
Other products 6.7 4 16 6.9 4 4
Cumulated sales 170.9 100 16 192.8 100 13
(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland
included

Sales growth and financial position

Sales growth sped up over the fourth quarter to 15%, 3 percentage
points higher than that of third quarter 2009. The markets of
Northern Europe ("Other EU") and the sublingual route drove this
progression but the markets of Southern Europe had an encouraging
recovery in growth over the last quarter. Other markets were affected
by a negative basis effect due to the strong growth achieved in 2008.

Organic growth, after restatement for foreign exchange effects
stood at 13% over the quarter and 12% over the full year.

As a consequence, results for the year will markedly improve:
operating profit and net profit as a percentage of sales should
remain close to the levels achieved in 2008 (16% and 11%,
respectively). The Company had a positive net cash position at the
end of the financial year.

The comprehensive 2009 results will be published on 16 March 2010
after close of trading.

As for 2010, the Group is currently expecting significant growth
and a further improvement in its results due to the limitation put on
R&D expenses.

Significant 4th quarter transactions and events

Following the mutual recognition procedure, Oralair(R)
(immunotherapy tablet for grass pollen) was granted a marketing
authorisation in 22 European countries in its adult and paediatric
indications on 27 November 2009.

The outstanding results of the study devoted to showing the
long-term sustained effect of Oralair(R) were announced on 7 December
2009. They significantly confirmed the clinical relevance of
Oralair(R). This study is being continued with a view to
demonstrating the persistence of the effect after completion of the
treatment (carry-over effect), which should be the subject of an
announcement at the end of 2010.

The Oralair(R) phase III clinical study in the US was completed
in good conditions. Talks are ongoing with the FDA on statistical
analysis matters. These exchanges have no impact on the results of
the study but must be concluded before the database is opened for
analysis. Consequently, the delivery of the preliminary results will
take place in a few weeks.

The authorisation to carry out a Phase III clinical study on
children for Actair(R) (immunotherapy tablet for dust mites) on 450
patients has been granted in Europe and patients are being recruited.
The preliminary results should be published in mid-2011.

The presentation of the clinical results obtained in 2009 and at
the start of 2010 will be the subject of a specific meeting, to be
organised shortly.

About Stallergenes

Stallergenes is a European biopharmaceutical laboratory
specialising in treatments by immunotherapy for the prevention and
treatment of allergy-related respiratory conditions, such as rhino
conjunctivitis, rhinitis and allergic asthma. Stallergenes is ranked
seventh among French pharmaceutical laboratories. A pioneer and a
leader in immunotherapy treatments by sublingual administration,
Stallergenes dedicates 21% (gross) of its sales to its Research and
Development activities, which are primarily directed at developing a
new therapeutic range enabling the provision of immunotherapy
treatments by sublingual tablets.

Stallergenes realised 2009 sales of EUR 193 million, with over
500,000 patients treated with Stallergenes desensitisation products.

Euronext Paris (Compartment B).

SBF 120 index.

ISIN code: FR0000065674

Reuters code: GEN.PA

Bloomberg code: GEN.FP

For further financial information, please visit our website:
http://www.stallergenes.com

ots Originaltext: Stallergenes
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Contacts: Albert Saporta, Chairman and CEO,
Tel.+33-1-55-59-20-04, Christian Thiry, Chief Financial Officer,
Tel.+33-1-55-59-20-95, e-mail: Diese E-Mail-Adresse ist gegen Spam Bots geschützt, Sie müssen JavaScript aktivieren, damit Sie es sehen können
Investor andAnalyst Relations: Lucile de Fraguier, Pavie Finance,
Tel.+33-1-42-15-04-39, e-mail: Diese E-Mail-Adresse ist gegen Spam Bots geschützt, Sie müssen JavaScript aktivieren, damit Sie es sehen können
Stallergenes PressRelations: Lise Lemonnier, Communication Officer,
Tel. +33-1-55-59-20-96,e-mail: Diese E-Mail-Adresse ist gegen Spam Bots geschützt, Sie müssen JavaScript aktivieren, damit Sie es sehen können